Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Clinical trial NCT02330783 · UNKNOWN
Trial details
- NCT number
- NCT02330783
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-01
- Primary completion
- 2018-12-01
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.